alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Hubert JOHNSON, Plaintiff in Error, v. The STATE of Oklahoma, Defendant in Error.

No. A-12381.

Criminal Court of Appeals of Oklahoma.

Jan. 9, 1957.

*1052Ralph Myers, Jr., El Reno, for plaintiff in error.

Mac Q. Williamson, Atty. Gen., Sam H. Lattimore, Asst. Atty. Gen., for defendant in error.

POWELL, Judge.

Hubert Johnson, hereinafter referred to as defendant, was charged by information filed in the county court of Canadian County with unlawful possession of intoxicating liquor, was tried before a jury, convicted and his punishment fixed at a fine of $100, and thirty days imprisonment in the county jail.

The within appeal was lodged in this court on July 25, 1956, and no brief has been filed, and when the case came on for oral argument, no one appeared on behalf of the defendant. We are not required •by terms of the applicable statute, 20 O.S. A. § 47, to file a formal opinion.

In Wilson v. State, 89 Okl.Cr. 421, 209 P.2d 512, 513, rehearing 212 P.2d 144, we said:

> “Where the defendant appeals from a judgment of conviction and neither any brief is filed nor appearance for oral argument- - made, this court will examine the record and evidence and if no error prejudicial to'' the substantial rights of the defendant is apparent, will affirm the judgment.”

' We have carefully read the record. We shall not treat the issues presented by the petition in error other than to say that the trial court did admit some hearsay evidence, and that the county attorney was permitted to ask one of the officers if he had not searched the premises before. It does appear that this was prior to occupation by the defendant. By reason of the matters mentioned, we feel that the fine of $100 imposed should be reduced to $50.

The judgment appealed from of a $100 .fine and thirty days in jail is modified to a fine of $50, and thirty days in the county jail, and as so modified is affirmed.

JONES, P. J., and BRETT, J„ concur.
<TABLE> <S> <C>

<ARTICLE>     5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheet and statements of operations found on pages F-3 and F-4 of the
Company's Form 10-KSB for the fiscal year ended December 31, 1998, and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                          12,957
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                16,518
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  16,518
<CURRENT-LIABILITIES>                           25,945
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       190,688
<OTHER-SE>                                    (200,115)
<TOTAL-LIABILITY-AND-EQUITY>                    16,518
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                19,301
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (19,301)
<EPS-PRIMARY>                                     (.01)
<EPS-DILUTED>                                     (.01)


</TABLE>
<PAGE>

                                                                   EXHIBIT 32(b)

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DUSA Pharmaceuticals, Inc. (the
"Company") on Form 10-Q for the period ending June 30, 2004, as filed with the
Securities and Exchange Commission (the "Report"), I, Peter M. Chakoutis, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

      3)    The Report fully complies with the requirements of Section 13(a) or
            15(d) of the Securities Exchange Act of 1934; and

      4)    The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Company.

Date: August 10, 2004                    /s/ Peter M. Chakoutis
                                         ---------------------------------------
                                         Peter M. Chakoutis
                                         Vice President,
                                         Chief Financial Officer (principal
                                         financial officer) and Controller
                                         (principal accounting officer)

A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its
staff upon request.
#### Benjamin J. FERNANDEZ, Petitioner, v. OFFICE OF PERSONNEL MANAGEMENT, Respondent.

No. 04-3425.

United States Court of Appeals, Federal Circuit.

Oct. 4, 2005.

Before MAYER, SCHALL, and LINN, Circuit Judges.

Judgment

PER CURIAM.

This CAUSE having been heard and considered, it is ORDERED and ADJUDGED:

*AFFIRMED. See*Fed. Cir. R. 36.
Instructions for EIA Laboratories: Actions to take following a non-negative test result for EIA

UPDATED October 2022

All samples with a non-negative result1 from an APHIS-Approved EIA testing laboratory must be 

forwarded to the National Veterinary Services Laboratories (NVSL) in Ames, IA for confirmatory testing

per VS Guidance 15201.1. Additional information is available at USDA APHIS | Equine Infectious Anemia 

(EIA). 

• First, notify your federal Area Veterinarian in Charge (AVIC)/ State Animal Health Official (SAHO).

• When forwarding sample(s) for EIA confirmation, the following steps are needed to ensure the 

VS 10-11 EIA form accurately reflects the test status of the horse. In cases where NVSL

confirmatory testing is ultimately negative, following these instructions avoids potential issues

with acceptance of the VS 10-11 form for movement, sale, or other uses. 

A. Complete a VS 10-4 submission document to submit the sample(s) to NVSL. 

• Select  surveillance as the “purpose of testing” and enter “EIA Confirmation” in Box 

9. Please include which test method(s) were used in with the kit serial number and 

expiration date in Box 22.

B. Include a copy of the VS 10-11 EIA form with the sample(s).

• Do not send the original VS 10-11 form. Each testing laboratory should retain these 

documents for a minimum of 2 years.

• If a paper VS 10-11 EIA form was submitted by the veterinarian, under the FOR 

LABORATORY USE ONLY fields at the bottom:

i. Select  “INTERIM RESULT REFERRED FOR CONFIRMATION”

ii. IMPORTANT! Leave the following fields BLANK until confirmatory testing is 

completed at NVSL

o Date Results Reported

o Official Test Result

o Test Type Used 

o Laboratory Remarks

• If using an electronic submission interface, select “INTERIM RESULT” in the electronic 

platform when forwarding.

C. Ship the samples with frozen gel ice pack(s); FedEx and UPS offer overnight shipping. 

D. Notification of incoming samples can be made by email to NVSL.Coggins@usda.gov with 

shipment tracking number and an attached copy of the VS 10-4 submission form.

• Upon receipt of the NVSL report, complete the original VS 10-11 EIA form as follows:

 Date Results Reported: Enter date of NVSL report

 Official Test Result: Enter NVSL result 

 Test Type Used: Select AGID and ELISA (NVSL will run both test types for confirmation)

 Laboratory Remarks: Enter “Result confirmed by NVSL under accession (insert NVSL 

accession number)

For questions, please email the NVSL Coggins Team at NVSL.Coggins@usda.gov or call NVSL at 515-337-

7551.

1 Non-negative refers to any result that is not negative, e.g., positive, suspect, discrepant, or equivocal
IV 

House Calendar No. 141 

114TH CONGRESS 

2D SESSION H. RES. 858 

[Report No. 114–741] 

Providing for consideration of the bill (H.R. 3590) to amend the Internal 

Revenue Code of 1986 to repeal the increase in the income threshold 

used in determining the deduction for medical care. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 12, 2016 

Mr. BURGESS, from the Committee on Rules, reported the following resolution; which was referred to the House Calendar and ordered to be printed 

RESOLUTION 

Providing for consideration of the bill (H.R. 3590) to amend 

the Internal Revenue Code of 1986 to repeal the increase 

in the income threshold used in determining the deduction for medical care. 

1 Resolved, That upon adoption of this resolution it 

2 shall be in order to consider in the House the bill (H.R. 

3 3590) to amend the Internal Revenue Code of 1986 to 

4 repeal the increase in the income threshold used in deter5 mining the deduction for medical care. All points of order 

6 against consideration of the bill are waived. The amendVerDate Sep 11 2014 22:17 Sep 12, 2016 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\HR858.RH HR858

sradovich on DSK3GMQ082PROD with BILLS
2 

•HRES 858 RH 

1 ment in the nature of a substitute recommended by the 

2 Committee on Ways and Means now printed in the bill 

3 shall be considered as adopted. The bill, as amended, shall 

4 be considered as read. All points of order against provi5 sions in the bill, as amended, are waived. The previous 

6 question shall be considered as ordered on the bill, as 

7 amended, and on any further amendment thereto, to final 

8 passage without intervening motion except: (1) one hour 

9 of debate equally divided and controlled by the chair and 

10 ranking minority member of the Committee on Ways and 

11 Means; and (2) one motion to recommit with or without 

12 instructions. 


sradovich on DSK3GMQ082PROD with BILLS

sradovich on DSK3GMQ082PROD with BILLS
House Calendar No. 141 

114TH CONGRESS 

2D SESSION H. RES. 858 

[Report No. 114–741] 

RESOLUTION 

Providing for consideration of the bill (H.R. 3590) 

in determining the deduction for medical care. repeal the increase in the income threshold used to amend the Internal Revenue Code of 1986 to 

SEPTEMBER 12, 2016 

Referred to the House Calendar and ordered to be 

printed 


sradovich on DSK3GMQ082PROD with BILLS
# C_2019230EN.01003801.xml

| 8.7.2019 | EN | Official Journal of the European Union | C 230/38 |
| --- | --- | --- | --- |

8.7.2019

EN

Official Journal of the European Union

C 230/38

---

Judgment of the General Court of 20 May 2019 — Fundación Tecnalia Research & Innovation v REA

(Case T-104/18) (1)

(Arbitration clause - Grant agreement concluded in the framework of the Seventh Framework Programme for research, technological development and demonstration activities (2007-2013) - Development of a system to monitor process and quality in the sector of industrial food production - Food-Watch Project - Overlap of the project with another project funded under the same programme - Information requirements on beneficiaries - Decision to demand repayment of the financial contribution paid under the grant agreement)

(2019/C 230/47)

Language of the case: Spanish

Parties

Applicant: Fundación Tecnalia Research & Innovation (San Sebastián, Spain) (represented by: P. Palacios Pesquera and M. Rius Coma, lawyers)

Defendant: Research Executive Agency (represented by: S. Payan-Lagrou and V. Canetti, acting as Agents, and by J. Rivas Andrés, lawyer)

Re:

Application based on Article 272 TFEU seeking, in essence, a declaration that the applicant is not required to repay the grant awarded for the project FP7-SME 2013 605879 (Food-Watch).

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Fundación Tecnalia Research & Innovation to pay the costs, including those of the interim proceedings. |
| --- | --- |

2.

Orders Fundación Tecnalia Research & Innovation to pay the costs, including those of the interim proceedings.

---

(1)  OJ C 134, 16.4.2018.

---
```

[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 72 Introduced in House (IH)]

114th CONGRESS
  1st Session
H. RES. 72

 Providing amounts for the expenses of the Committee on Agriculture in 
                  the One Hundred Fourteenth Congress.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 2, 2015

 Mr. Conaway submitted the following resolution; which was referred to 
                 the Committee on House Administration

_______________________________________________________________________

                               RESOLUTION

 
 Providing amounts for the expenses of the Committee on Agriculture in 
                  the One Hundred Fourteenth Congress.

    Resolved,

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES.

    For the expenses of the Committee on Agriculture (hereafter in this 
resolution referred to as the ``Committee''), including the expenses of 
all staff salaries, there shall be paid, out of the applicable accounts 
of the House of Representatives for committee salaries and expenses, 
not more than $10,173,096 for the One Hundred Fourteenth Congress.

SEC. 2. SESSION LIMITATIONS.

    Of the amount specified in section 1--
            (1) not more than $5,086,548 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2015, and ending immediately before noon on January 
        3, 2016; and
            (2) not more than $5,086,548 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2016, and ending immediately before noon on January 
        3, 2017.

SEC. 3. VOUCHERS.

    Payments under this resolution shall be made on vouchers authorized 
by the Committee, signed by the Chairman of the Committee, and approved 
in the manner directed by the Committee on House Administration.

SEC. 4. REGULATIONS.

    Amounts made available under this resolution shall be expended in 
accordance with regulations prescribed by the Committee on House 
Administration.
                                 <all>
```
50 P.3d 973

SUPREME COURT OF HAWAI'I

#### Donnelly v. Donnelly

23462

06/10/2002

Denied

98 Hawai'i 280, 47 P.3d 747
#### UNITED STATES of America, Plaintiff-Appellee, v. Jose Jorge GONZALEZ-ACOSTA, Defendant-Appellant.

No. 05-40052

Summary Calendar.

United States Court of Appeals, Fifth Circuit.

Oct. 7, 2005.

James Lee Turner, Assistant U.S. Attorney, U.S. Attorney’s Office Southern District of Texas, Houston, TX, for PlaintiffAppellee.

Timothy William Crooks, Assistant Federal Public Defender, Marjorie A. Meyers, Federal Public Defender, Federal Public Defender’s Office Southern District of Texas, Houston, TX, for Defendant-Appellant.

Before JONES, WIENER, and DeMOSS, Circuit Judges.

PER CURIAM: *

Jose Jorge Gonzalez-Acosta appeals his guilty-plea conviction and sentence for illegal reentry after deportation in violation of 8 U.S.C. § 1326(a) and (b). Gonzalez-Acosta argues that, in light of *United States v. Booker,*— U.S. -, 125 S.Ct. 738, 160 L.Ed.2d 621 (2005), the district *496court plainly erred in sentencing him under a mandatory guidelines system.

We review for plain error. *See United States v. Valenzuela-Quevedo,*407 F.3d 728, 732 (5th Cir.2005), *cert. denied,*— U.S. -, — S.Ct. -, — L.Ed.2d -, 2005 WL 1811485 (2005) (No. 05-5556); *see also United States v. Malveaux,*411 F.3d 558, 560 n. 9 (5th Cir.2005), *cert. denied*— U.S. -, — S.Ct. -, -— L.Ed.2d -, 2005 WL 1670813 (July 11, 2005) (No. 05-5297). After *Booker,*it is clear that application of the federal sentencing guidelines in their mandatory form constitutes error that is plain. *Valenzuela-Quevedo,*407 F.3d at 733-34. However, nothing in the record indicates that the plain error affected Gonzalez-Acosta’s substantial rights. *See id.*

Gonzalez-Acosta argues that the “felony” and “aggravated felony” provisions of 8 U.S.C. § 1326(b)(1) and (2) are unconstitutional in light of *Apprendi v. New Jersey,*530 U.S. 466, 120 S.Ct. 2348, 147 L.Ed.2d 435 (2000). Gonzalez-Acosta acknowledges that his argument is foreclosed by *Almendarez-Torres v. United States,*523 U.S. 224, 118 S.Ct. 1219, 140 L.Ed.2d 350 (1998), but he wishes to preserve the issue for Supreme Court review in light of *Apprendi. Apprendi*did not overrule *Almendarez-Torres. See Apprendi,*530 U.S. at 489-90; *United States v. Dabeit,*231 F.3d 979, 984 (5th Cir.2000). Thus, we must follow *Almendarez-Torres*unless the Supreme Court overrules it. *Dabeit,*231 F.3d at 984.

AFFIRMED.

*

 Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
An Equal Opportunity Provider and Employer

CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 19-04

TO: Biologics Licensees, Permittees, and Applicants

Directors, Center for Veterinary Biologics

Veterinary Services Leadership Team

FROM: Byron E. Rippke

Director

SUBJECT: Name Change for Biologicals Containing Mycobacterium avium

subspecies paratuberculosis, formerly Mycobacterium paratuberculosis

I. PURPOSE

The CVB’s intended purpose for this Notice is to inform licensees, permittees, and 

applicants of a change in the True Name of applicable products.

II. BACKGROUND

Mycobacterium paratuberculosis has been renamed Mycobacterium avium

subspecies paratuberculosis as a result of taxonomic investigations. The scientific 

community has endorsed this new name and it is included in the List of Prokaryotic 

Names with Standing in Nomenclature: See http://www.bacterio.net/index.html. 

Since the CVB uses standard nomenclature when reasonably possible, CVBassigned True Names for products containing this organism will now include

“Mycobacterium Avium Subspecies Paratuberculosis.”

III. ACTION (or POLICY)

The CVB will use the new nomenclature for products in the prelicense stage. For 

licensed and permitted products, Outlines of Production and labelling should be 

revised. All affected firms must comply within two years of the date of this notice.

The CVB will reissue a new license or permit within 60 days of the date of the 

notice. It is not necessary for the firm to make a submission to request reissuance of 

a new license with an updated True Name.

IV. IMPLEMENTATION/ APPLICABILITY

This action is effective immediately.

Animal and Plant

Health Inspection

Service

Veterinary Services

Center for Veterinary 

Biologics

1920 Dayton Avenue

PO Box 844

Ames, IA 50010

(515) 337-6100
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF ARONEX PHARMACEUTICALS, INC. SET FORTH IN THE COMPANY'S
FORM 10-K FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       4,179,000
<SECURITIES>                                37,209,000
<RECEIVABLES>                                   78,000
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            35,334,000
<PP&E>                                       5,021,000
<DEPRECIATION>                               2,869,000
<TOTAL-ASSETS>                              44,281,000
<CURRENT-LIABILITIES>                        3,658,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        15,000
<OTHER-SE>                                  40,462,000
<TOTAL-LIABILITY-AND-EQUITY>                44,281,000
<SALES>                                              0
<TOTAL-REVENUES>                             4,362,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             173,000
<INCOME-PRETAX>                            (8,030,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (8,030,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (8,030,000)
<EPS-PRIMARY>                                   (0.62)
<EPS-DILUTED>                                   (0.62)


</TABLE>
SUPREME COURT OF HAWAI'I

May 20, 1997

19896

#### Apao v. State

Affirmed
(1)
    
    The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.
  /s/ Paula J. MeilerPaula J. Meiler 
Senior Vice Presidentand Chief Financial Officer 
 *
    
    This certification is being furnished as required by Rule 13a-14(b) under the Securities Exchange
Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States
Code, and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise
subject to the liability of that section. This certification shall not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as
otherwise stated in such filing.